Advertisement
Person › Details
Mark Alles (Celgene Corporation (Nasdaq: CELG))
Alles, Mark (Celgene 201306 EVP + Global Head Hematology + Oncology)
Organisation | Celgene Corporation (Nasdaq: CELG) | |
Group | Bristol Myers Squibb (BMS) (Group) | |
Product | cancer drug | |
Record changed: 2023-05-03 |
Advertisement
More documents for Mark Alles
- [1] Celgene Corporation. (3/6/18). "Press Release: Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy". Summit, NJ....
- [2] Celgene Corporation. (1/22/18). "Press Release: Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy". Summit, NJ & Seattle, WA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top